Latest United States News

Patrys has formed an international Clinical Advisory Committee to help shape the next stages of RLS-2202, its injectable quetiapine candidate for delirium in acute-care settings. The appointments add recognised expertise in delirium research, intensive care and trial design, but do not yet provide clinical efficacy or regulatory evidence.

Latrobe Magnesium has detailed the capital, feedstock and valuation assumptions behind its proposed 50 ktpa magnesium plant in South Carolina. The project retains strong headline economics, but funding, feasibility work and a final investment decision remain ahead.

WAM Global’s portfolio earnings grew 18% in FY2026, but valuation compression and currency losses left the investment portfolio down about 4.2% in Australian-dollar terms. The listed investment company declared a 13.2 cents per share fully franked full-year dividend, backed by a stated 5.2 years of dividend coverage.

Fulcrum Lithium has promoted Chief Operating Officer Scott Keenan to Managing Director, placing the executive who led its Alkali Flats discovery in charge of the company’s next project phase. The appointment comes with a $360,000 annual salary and a proposed 4 million performance-rights package subject to shareholder approval.

ION Video has secured an oversubscribed $4.25 million placement to fund independent trials of its video technology, with directors and management committing a further $1.2 million subject to shareholder approval. The capital will be used to test whether ION’s architecture can deliver measurable technical and financial benefits in real operating environments.

Volt Resources has secured US$5.4 million in fully government-funded support for its US graphite refinery and customer application centre. The award is positive for project funding, but the company’s ASX securities remain suspended as it works with the exchange to satisfy reinstatement requirements.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

Trek Metals has secured a nine-month option to acquire the 154-claim Matrix Manganese Project in Arizona for a total potential cash consideration of A$200,000. The deal offers a low-cost route into a US critical-minerals opportunity, but carries a significant related-party consideration because CEO Derek Marshall owns about 66.67% of the vendor.

Latrobe Magnesium is shifting its growth priority to a proposed 50 ktpa magnesium plant in South Carolina, backed by 32 ktpa of non-binding customer interest and a 20-year feedstock agreement. The project carries substantial indicative economics, but still needs funding, site acquisition, feasibility work, permits and binding offtake contracts.

JPMorgan US 100Q Equity Premium Income ETF (ASX:JPH) lifted operating profit to A$15.678 million for the year ended 30 June 2026, while net assets rose to A$106.991 million. The fund is also preparing to move its underlying exposure from a Nasdaq-listed ETF to an Irish UCITS vehicle traded in London, with total management fees and costs unchanged at 0.40% a year.

JPMorgan Global Research Enhanced Index Equity Trust reported a sharp rise in operating profit and net assets for the year ended 30 June 2026, powered largely by fair value gains across its global portfolio. Distributions also increased substantially, particularly for hedged classes, although the report does not show whether the Fund outperformed its benchmark.

JPMorgan Equity Premium Income ETF grew net assets to $167.99 million while operating profit plunged to $740,000 as fair-value losses widened. The fund is also preparing to switch its underlying ETF from NYSE Arca to the London Stock Exchange without changing its investment objective or stated total fees and costs.